Literature DB >> 33938689

Management of Primary Focal Hyperhidrosis: An Algorithmic Approach.

Vivian Liu, Mehdi Farshchian, Geoffrey A Potts.   

Abstract

Hyperhidrosis (HH) is defined as perspiration beyond the level required to maintain temperature regulation. HH affects nearly 4.8% of the population in the United States. It can have a great impact on patient’s quality of life by disturbing daily activity, performance, confidence, social interactions, and mental health. In the majority of patients with HH (93%), the etiology of excess sweating is idiopathic, which classifies it as primary focal HH. Mild HH may be controlled with topical antiperspirants and lifestyle modifications. Based on the location of involvement, iontophoresis and botulinum toxin may be considered if the patient does not respond to topical therapies. Despite minimizing sweating, chronic use of systemic anticholinergics, in particular oxybutynin, may result in detrimental adverse effects such as dementia. Local surgery, radiofrequency, microwave, and lasers are other potential modalities for HH. Sympathectomy can be a last resort for the treatment of focal HH of the palmar, plantar, axillary, and craniofacial areas after failure of less invasive therapeutic options. In this review, we conducted a comprehensive search in the PubMed electronic database to summarize an algorithmic approach for the treatment of HH. This can help broaden options for managing this difficult disease. J Drugs Dermatol. 20(5): doi:10.36849/JDD.5774.

Entities:  

Year:  2021        PMID: 33938689     DOI: 10.36849/JDD.5774

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  2 in total

1.  Botulinum Toxin Type A for Treatment of Forehead Hyperhidrosis: Multicenter Clinical Experience and Review from Literature.

Authors:  Anna Campanati; Emanuela Martina; Stamatis Gregoriou; George Kontochristopoulos; Matteo Paolinelli; Federico Diotallevi; Giulia Radi; Ivan Bobyr; Barbara Marconi; Giulio Gualdi; Paolo Amerio; Annamaria Offidani
Journal:  Toxins (Basel)       Date:  2022-05-27       Impact factor: 5.075

2.  Antagonist of Chrna1 prevents the pathogenesis of primary focal hyperhidrosis.

Authors:  Jian-Bo Lin; Nan-Long Lin; Xu Li; Ming-Qiang Kang
Journal:  Ann Clin Transl Neurol       Date:  2022-04-08       Impact factor: 5.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.